The Akt pathway in oncology therapy and beyond (Review)

被引:307
作者
Nitulescu, George Mihai [1 ]
Van De Venter, Maryna [2 ]
Nitulescu, Georgiana [1 ]
Ungurianu, Anca [1 ]
Juzenas, Petras [3 ]
Peng, Qian [3 ]
Olaru, Octavian Tudorel [1 ]
Gradinaru, Daniela [1 ]
Tsatsakis, Aristides [4 ]
Tsoukalas, Dimitris [4 ]
Spandidos, Demetrios A. [5 ]
Margina, Denisa [1 ]
机构
[1] Carol Davila Univ Med & Pharm, Fac Pharm, 6 Traian Vuia, Bucharest 020956, Romania
[2] Nelson Mandela Univ, Dept Biochem & Microbiol, ZA-6031 Port Elizabeth, South Africa
[3] Oslo Univ Hosp, Dept Pathol, Radiumhosp, N-0379 Oslo, Norway
[4] Univ Crete, Fac Med, Dept Forens Sci & Toxicol, Iraklion 71003, Greece
[5] Univ Crete, Sch Med, Lab Clin Virol, Iraklion 71003, Greece
关键词
phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin pathway; apoptosis; cancer; neurodegenerative disease; diabetes; clinical trial; repurposing drugs; natural products; PI3K/AKT SIGNALING PATHWAY; TRICYCLIC NUCLEOSIDE PHOSPHATE; PROTEIN-KINASE; DIABETES-MELLITUS; PHASE-I; MOLECULAR-MECHANISMS; INHIBITOR MK-2206; CANCER-CELLS; NASOPHARYNGEAL CARCINOMA; INSULIN-RESISTANCE;
D O I
10.3892/ijo.2018.4597
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Protein kinase B (Akt), similar to many other protein kinases, is at the crossroads of cell death and survival, playing a pivotal role in multiple interconnected cell signaling mechanisms implicated in cell metabolism, growth and division, apoptosis suppression and angiogenesis. Akt protein kinase displays important metabolic effects, among which are glucose uptake in muscle and fat cells or the suppression of neuronal cell death. Disruptions in the Akt-regulated pathways are associated with cancer, diabetes, cardiovascular and neurological diseases. The regulation of the Akt signaling pathway renders Akt a valuable therapeutic target. The discovery process of Akt inhibitors using various strategies has led to the identification of inhibitors with great selectivity, low side-effects and toxicity. The usefulness of Akt emerges beyond cancer therapy and extends to other major diseases, such as diabetes, heart diseases, or neurodegeneration. This review presents key features of Akt structure and functions, and presents the progress of Akt inhibitors in regards to drug development, and their preclinical and clinical activity in regards to therapeutic efficacy and safety for patients.
引用
收藏
页码:2319 / 2331
页数:13
相关论文
共 177 条
[1]   A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors [J].
Aghajanian, Carol ;
Bell-McGuinn, Katherine M. ;
Burris, Howard A., III ;
Siu, Lillian L. ;
Stayner, Lee-Ann ;
Wheler, Jennifer J. ;
Hong, David S. ;
Kurkjian, Carla ;
Pant, Shubham ;
Santiago-Walker, Ademi ;
Gauvin, Jennifer L. ;
Antal, Joyce M. ;
Opalinska, Joanna B. ;
Morris, Shannon R. ;
Infante, Jeffrey R. .
INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) :1016-1025
[2]   Targeted Regulation of PI3K/Akt/mTOR/NF-κB Signaling by Indole Compounds and their Derivatives: Mechanistic Details and Biological Implications for Cancer Therapy [J].
Ahmad, Aamir ;
Biersack, Bernhard ;
Li, Yiwei ;
Kong, Dejuan ;
Bao, Bin ;
Schobert, Rainer ;
Padhye, Subhash B. ;
Sarkar, Fazlul H. .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (07) :1002-1013
[3]   Perturbations of the AKT signaling pathway in human cancer [J].
Altomare, DA ;
Testa, JR .
ONCOGENE, 2005, 24 (50) :7455-7464
[4]   Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: Role of Akt and extracellular signal-regulated kinase signaling pathways [J].
Aoki, Hiroshi ;
Takada, Yasunari ;
Kondo, Seiji ;
Sawaya, Raymond ;
Aggarwal, Bharat B. ;
Kondo, Yasuko .
MOLECULAR PHARMACOLOGY, 2007, 72 (01) :29-39
[5]   A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis [J].
Arceci, Robert J. ;
Allen, Carl E. ;
Dunkel, Ira J. ;
Jacobsen, Eric ;
Whitlock, James ;
Vassallo, Robert ;
Morris, Shannon R. ;
Portnoy, Alison ;
Reedy, Beth Ann ;
Smith, Deborah A. ;
Noble, Robert ;
Murnane, Amy ;
Cornfeld, Mark ;
Rodriguez-Galindo, Carlos ;
Heaney, Mark L. ;
McClain, Kenneth ;
Vaiselbuh, Sarah .
PEDIATRIC BLOOD & CANCER, 2017, 64 (05)
[6]   Thermal behavior of some vanadyl complexes with flavone derivatives as potential insulin-mimetic agents [J].
Badea, Mihaela ;
Olar, Rodica ;
Uivarosi, Valentina ;
Marinescu, Dana ;
Aldea, Victoria ;
Barbuceanu, Stefania Felicia ;
Nitulescu, George Mihai .
JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, 2011, 105 (02) :559-564
[7]   A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers [J].
Banerji, Udai ;
Dean, Emma J. ;
Alejandro Perez-Fidalgo, J. ;
Batist, Gerald ;
Bedard, Philippe L. ;
You, Benoit ;
Westin, Shannon N. ;
Kabos, Peter ;
Garrett, Michelle D. ;
Tall, Mathew ;
Ambrose, Helen ;
Barrett, J. Carl ;
Carr, T. Hedley ;
Cheung, S. Y. Amy ;
Corcoran, Claire ;
Cullberg, Marie ;
Davies, Barry R. ;
de Bruin, Elza C. ;
Elvin, Paul ;
Foxley, Andrew ;
Lawrence, Peter ;
Lindemann, Justin P. O. ;
Maudsley, Rhiannon ;
Pass, Martin ;
Rowlands, Vicky ;
Rugman, Paul ;
Schiavon, Gaia ;
Yates, James ;
Schellens, Jan H. M. .
CLINICAL CANCER RESEARCH, 2018, 24 (09) :2050-2059
[8]   Group I metabotropic glutamate receptors reduce excitotoxic injury and may facilitate neurogenesis [J].
Baskys, A ;
Bayazitov, D ;
Fang, L ;
Blaabjerg, M ;
Poulsen, FR ;
Zimmer, J .
NEUROPHARMACOLOGY, 2005, 49 :146-156
[9]   Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling [J].
Beckwitt, Colin H. ;
Shiraha, Keisuke ;
Wells, Alan .
PLOS ONE, 2018, 13 (05)
[10]   Activation of AKT kinases in cancer: Implications for therapeutic targeting [J].
Bellacosa, A ;
Kumar, CC ;
Di Cristofano, A ;
Testa, JR .
ADVANCES IN CANCER RESEARCH, VOL 94, 2005, 94 :29-+